RBC Capital Maintains Outperform on Medtronic, Lowers Price Target to $110
RBC Capital analyst Shagun Singh maintains Medtronic (NYSE:MDT) with a Outperform and lowers the price target from $122 to $110.
Medtronic Announced ADAPT Study Results Published in The Lancet Diabetes & Endocrinology Show Improved Glycemic Control and Treatment Satisfaction among Those Using MiniMed 780G System vs Insulin Injections
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced results from the Medtronic ADAPT study were published in The Lancet Diabetes & Endocrinology.
Medtronic Announces Partnership With Biointellisense For Exclusive U.S. Distribution Of Multi-parameter Wearable For Continuous Remote Patient Monitoring From In-Hospital To Home
Partnership reflects commitment to patient safety; BioButton® wearable offers up to 1,440 vital signs measurements daily, monitoring patients transitioning from higher to lower acuity settings
Technology
Medtronic Recalls HeartWare HVAD System Batteries For Electrical Faults
Medtronic Plc (NYSE:MDT) is recalling HeartWare HVAD System batteries because they may experience electrical faults that cause the system to fail…
One Analyst Is Bullish On Medtronic, Another Is Not Post Q1 Earnings
Citi says that Medtronic plc (NYSE: MDT) delivered better-than-expected FY1Q23 results, reiterating FY23 guidance despite the ongoing litany of pressures impacting Medtech.
Wells Fargo Maintains Equal-Weight Rating for Medtronic: Here’s What You Need To Know
Wells Fargo has decided to maintain its Equal-Weight rating of Medtronic (NYSE:MDT) and lower its price target from $104.00 to $96.00.
Shares of Medtronic are trading down 0.43% over the last 24 hours, at $89.83 per share.
A move to $96.00 would account for a 6.87% increase from the current share price.
15 Analysts Have This to Say About Medtronic
Analysts have provided the following ratings for Medtronic (NYSE:MDT) within the last quarter:
